116112-44-8

Basic information

• Product Name: Benzenebutanoic acid, a-[(acetylthio)methyl]-
• CAS NO: 116112-44-8
• Molecular Formula: C13H16O3S
• Molecular Weight: 252.334
• Mol File: 116112-44-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzenebutanoic acid, a-[(acetylthio)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanoic acid, a-[(acetylthio)methyl]-(116112-44-8)
• EPA Substance Registry System: Benzenebutanoic acid, a-[(acetylthio)methyl]-(116112-44-8)

Safety Data

• Hazardous Substances Data: 116112-44-8(Hazardous Substances Data)

Upstream product

• 128038-39-1 2-methylene-4-phenylbutanoic acid 
• 507-09-5 tiolacetic acid 
• 110-89-4 piperidine 
• 79-37-8 oxalyl dichloride 
• 122-87-2 N-(hydroxyphenyl)glycine 
• 56405-21-1 DL-p-hydroxyphenylglycine methyl ester 
• 3709-21-5 2-phenylethylmalonic acid 
• 89074-52-2 1,1-dimethylethyl 2-(2-phenylethyl)-3-oxobutanoate 
• 84793-30-6 1,1-dimethylethyl α-methylenebenzenebutanoate 
• 103-63-9 1-phenyl-2-bromoethane 
• 156757-40-3 1,1-dimethylethyl α-<((R,S)-acetylthio)methyl>benzenebutanoate 

Downstream Products

• 206765-58-4 2-[(5-Benzyl)thien-2yl]-N-[2-(acetylthiomethyl)-4-phenylbutyryl]glycine Ethyl Ester 
• 156792-22-2 (S)-2-((R)-2-Acetylsulfanylmethyl-4-phenyl-butyrylamino)-4-methylsulfanyl-butyric acid ethyl ester 
• 156792-21-1 (S)-2-((S)-2-Acetylsulfanylmethyl-4-phenyl-butyrylamino)-4-methylsulfanyl-butyric acid ethyl ester 

Relevant articles and documents

Beta-thiopropionyl-amino acid derivatives and their use as beta-lactamase inhibitors

PCT No. PCT/EP97/05709 Sec. 371 Date Apr. 7, 1999 Sec. 102(e) Date Apr. 7, 1999 PCT Filed Oct. 10, 1997 PCT Pub. No. WO98/17639 PCT Pub. Date Apr. 30, 1998Mercapto amino acid derivatives of formula (I), wherein R is hydrogen, a salt-forming cation of a in vivo hydrolysable ester-forming group; R1 is selected from (a) and (b) in which A is a monocyclic aryl or heteroaryl ring and B is a monocyclic aryl, alicyclic or heterocyclic ring, C and D are independently -Zp-(CR8CR9)q- or -(CR8CR9)q-Zp- where p is 0 or 1, q is 0 to 3 provided that p+q in C is not 0, R8 and R9 are independently hydrogen or (C1-6)alkyl or together represent oxo and Z is O, NR10 or S(O)x where R10 is hydrogen, (C1-6)alkyl or aryl(C1-6)alkyl and x is 0-2, and wherein C and D are linked ortho to one another on each of the rings A and B in formula (b); R2 is hydrogen, (C1-6)alkyl or aryl(C1-6)alkyl; R3 is hydrogen, (C1-6)alkyl optionally substituted by up to three halogen atoms, (C3-7)cycloalkyl, fused aryl(C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl-(CH2)m-X-(CH2)n, heterocyclyl or heterocyclyl-(CH2)m-X-(CH2)n, where m is 0 to 3, n is 1 to 3 and X is O or S(O)x where x is 0-2 or a bond; R4 is hydrogen or an in vivo hydrolysable acyl group; and R5 and R6 are independently hydrogen and (C1-6)alkyl or together represent (CH2)r, where r is 2 to 5; for use in treatment of bacterial infections in humans or animals by administration in combination with a beta -lactam antiobiotic.

beta -thiopropionyl-aminoacid derivatives and their use as beta -lactamase inhibitors

PCT No. PCT/EP97/00516 Sec. 371 Date Jan. 13, 1999 Sec. 102(e) Date Jan. 13, 1999 PCT Filed Feb. 3, 1997 PCT Pub. No. WO97/30027 PCT Pub. Date Aug. 21, 1997A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a beta -lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R1 is hydrogen, (C1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C1-6)alkylcarbonyloxy, (C1-6)alkoxycarbonyl, formyl or (C1-6)alkylcarbonyl group, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl(C1-6)alkyl, heterocyclyl or heterocyclyl(C1-6)alkyl; R2 is hydrogen, (C1-6)alkyl or aryl(C1-6)alkyl; R3 is hydrogen, (C1-6)alkyl optionally substituted by up to three halogen atoms, (C3-7)cycloalkyl, fused aryl(C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl-(CHR10)m-X-(CHR11)n, heterocyclyl or heterocyclyl-(CHR10)m-X-(CHR11)n, where m is 0 to 3, n is 1 to 3, each R10 and R11 is independently hydrogen or (C1-4)alkyl and X is O, S(O)x where x is 0-2, or a bond; R4 is hydrogen, or an in vivo hydrolysable acyl group; and R5 and R6 are independently hydrogen and (C1-6)alkyl or together represent (CH2)p where p is 2 to 5. Some compounds are claimed per se.

Mercaptoacyl amino acid inhibitors of atriopeptidase. 1. Structure- activity relationship studies of methionine and S-alkylcysteine derivatives

A broad series of N-(3-mercaptoacyl) amino acid derivatives was evaluated for their ability to inhibit atriopeptidase (neutral endopeptidase, EC 3.4.24.11) in vitro and in vivo. Structural parameters studied were (i) the substituent on the 2-position of the 3-mercaptopropionyl moiety, (ii) the amino acid component, (iii) the S-terminal derivative, and (iv) the C- terminal derivative. Optimum activity was observed for derivatives of methionine and S-alkylcysteines. N-[3-Mercapto-2(S)-[(2- methylphenyl)methyl]-1-oxopropyl]-L-methionine was identified as a highly effective inhibitor of atriopeptidase meriting evaluation as a potential cardiovascular therapeutic agent.